Cambridge-based CN Bio Innovations is one of the leading bioengineering companies specialising in innovative lab technologies. Its technologies can replicate the micro-environments, biological processes, and cell-cell interactions that occur in vivo and bridge the gap between traditional cell culture assays as well as human studies.
CN Bio Innovations improves drug discovery and reduces research and development costs. This bioengineering company aims to provide systems that generate clinically translatable data that can enhance the development of tomorrow’s medicines.
Raises €8.05M funding
In a recent development, CN Bio Innovations raised $9 million (nearly €8.05 million) funding in a round led by CITIC Securities Investment Co. Ltd. along with existing investor CN Innovations Holdings Ltd.
With the funding, CN Bio Innovations will focus on the commercial development of its products. Also, it will intend to strengthen its position in the U.S., its key market and expand operations across Europe. Besides these, the company will also drive sales of its products and services such as the PhysioMimix platform.
What does it do?
The cell culture company that has developed organ-on-chip laboratory instruments. These are meant to improve both the efficiency and accuracy of drug discovery. Led by Dr. David Hughes, this UK company provides micro-physiological systems enabling researchers to stay toxicology, drug metabolism, and specific disease models on single-organ and multi-organ systems.
Relocation within the UK
In addition to the new funding round, CN Bio Innovations announced the relocation plans. It will move its headquarters to the Cambridge Science Park, UK, which comprises a laboratory space of 4000 sq.ft.
Stock photo from nobeastsofierce/Shutterstock
Stay tuned to Silicon Canals for more European technology news.